Issue Eighteen | Winter 2015 Health and Technology

Total Page:16

File Type:pdf, Size:1020Kb

Issue Eighteen | Winter 2015 Health and Technology Medical technology About the entrepreneurs who are developing wearables, home diagnostics, smart products and apps to put patients in the driving seat Personalised medicine Using DNA analysis and big data to detect diseases and help physicians devise the right treatment for each patient New paradigms for healthcare Business leaders bringing affordable and accessible treatment to people in emerging markets Healthy returns Pictet on investing in healthcare stocks An inspirational leader The Japanese maestro ISSUE EIGHTEEN | WINTER 2015 who brings out the best HEALTH AND TECHNOLOGY in young musicians FOREWORD Health matters to all of us: we want to live longer and better lives as our standards of living rise. In this issue of Pictet Report, we take a look at some exciting developments in the diagnosis and treatment of illnesses, and at new models for providing affordable and accessible healthcare. The most significant factor in improving healthcare today is technological innovation – in particular, the falling costs of DNA sequencing and the enormous expansion of computer processing power. So much of this issue is devoted to interviews with exceptional entrepreneurs who are harnessing such developments to analyse data on a large scale, diagnose illnesses and select personalised treatments. Their products include wearable devices, home diagnostic machines, and smart products and apps which can help people take control of their own health. Two physicians told us about new approaches they have devised to treat conditions such as Alzheimer’s and cancer. We spoke to a Swiss company that makes intricate titanium implants used to treat bone diseases such as osteoarthritis. And the Director of Geneva’s new Campus Biotech explained how he is bringing together different disciplines to find cures for diseases that have defeated large drug companies. We also interviewed two entrepreneurs behind different models for providing healthcare in developing countries and emerging markets. And two Pictet analysts told us how innovation in healthcare has made the companies behind it attractive stocks for investors. Finally, the philanthropist profiled in this issue is Seiji Ozawa, the distinguished Japanese conductor who has set up international academies to help talented young musicians realise their potential. We hope that you will find this issue interesting – suggesting, as it does, that we are entering a new era in healthcare. Rémy Best Managing Partner Pictet Group Cover image – Microscope slides with tissue specimens, USC Westside Cancer Center & Center for Applied Molecular Medicine Pictet editorial team – Ninja Struye de Swielande Design & editorial consultancy – Forth Studio | Writer – John Willman Photography – Alex Teuscher, Aurélien Bergot, Zakaria Zainal, Roderick Aichinger, Jan Sondergaard, Oliver Oettli, Jean-Marc Falconnet, Carlotta Cardana, Patrick Strattner, Emmanuel Fradin, Wes Sumner, Nicolas Righetti and Christoffer Rudquist Winter 2015 For subscription information please contact: [email protected] PERSONALISED MEDICINE p15 Dr Richard Isaacson p37 Dr David Agus p41 Sophia Genetics p47 Stefan Roever Reducing the risk of Alzheimer’s Personalised healthcare Data-driven medicine DNA Sequencing SWISS-MADE PATIENT EMPOWERMENT p23 Medartis p21 Atonomics p31 Sentrian p45 Withings High-precision bone implants Diagnostic testing for the people Remote disease management Smart products and apps NEXT GENERATION HEALTHCARE PHILANTHROPY PICTET'S VIEW p5 Benoît Dubuis p13 Fullerton Healthcare p28 Seven Seas p9 Seiji Ozawa p51 Pictet on Switzerland’s Health Valley Accessible and affordable Technologies The philanthropist healthcare equities treatment for all A new paradigm for Healthy returns in universal healthcare an ageing world LOCATIONS 1 California 6 Denmark 6 Stefan Roever Atonomics 3 Dr David Agus 7 Kenya 5 4 2 New York Seven Seas 9 Dr Richard Isaacson Technologies 1 2 9 3 United Kingdom 8 Singapore Sentrian Fullerton 4 France Healthcare Withings 9 Japan and 5 Switzerland Switzerland 7 8 Benoît Dubuis Seiji Ozawa Sophia Genetics Malawi Medartis pictet report | winter 2015 contents health and technology 3 next generation healthcare: pictet report | winter 2015 4 switzerland’s health valley health and technology NEXT GENERATION HEALTHCARE SWITZERLAND'S HEALTH VALLEY Benoît Dubuis The Director of Geneva’s Campus Biotech is creating a new biotechnology and medical technology centre, bringing together different disciplines to find treatments that will save lives and improve the quality of life for patients Since the beginning of modern pharmaco- meets the needs of an ageing popu- ‘The confluence logy, the treatment of patients has relied on lation, that it can be financed and of innovations advances in medicine and biology to devise that it can respond to new needs such therapies that can cure or alleviate their as chronic diseases which now in computing, conditions. Today, new approaches focus on consume so much of health budgets.’ engineering and specific biological targets, identify predis- The opportunity to create Campus biotechnology will positions to diseases and find personalised Biotech came in 2012 when the revolutionise treatments that use digital technologies to pharmaceutical giant Merck Serono put patients in control. closed its base in a former indus- the treatment of trial area of Geneva, leading to health problems’ Campus Biotech, an ultra-modern the loss of more than a thousand research centre in Geneva, is aiming jobs. To retain their expertise, a to put itself at the forefront of this consortium backed by the canton new approach, bringing together of Geneva and the federal govern- a wide range of skills in biotechnology ment bought most of the build- and medical technology to find cures ing a year later, with plans to open for diseases that have defeated large a new type of research hub. drug companies. Its new approach Two universities are at the centre to research and development will of the project: the University of create opportunities for collabora- Geneva and École Polytechnique Fédé- tion between researchers, technolo- rale de Lausanne (EPFL), Lausanne’s gists, computer specialists and the technical university – both of which drugs industry to bring innovative are moving research groups to the products to market. campus. Two wealthy philanthropists ‘We are at a turning point in also contributed: the Bertarelli family, the history of medicine,’ says Benoît the descendents of Serono’s founder, Dubuis, Executive Director of Campus which has previously endowed neuro- Biotech. ‘The confluence of innova- science programmes at EPFL and tions in computing, engineering and Harvard; and Hansjörg Wyss, founder biotechnology will revolutionise the of a medical devices business, who is treatment of health problems. Our also endowing the Wyss Centre for Bio- goals are to ensure that medicine and Neuro-Engineering at the Campus. pictet report | winter 2015 next generation healthcare: health and technology switzerland’s health valley 5 With these resources, the new centre will come from the interface between is focusing on neuroscience – The aim is to have these two approaches,’ says Dr Dubuis. a discipline for which both universities platforms open Dr Dubuis believes that the are noted. This leadership position was Campus will be able to find market to anyone to work boosted when the European Union solutions to intractable neurological decided in 2013 to support EPFL’s in – researchers, diseases, especially mental illnesses Human Brain Project, which aims digital experts, and those connected with ageing such to stimulate the brain using comput- engineers, as Alzheimer’s. ‘Most large pharma- ers and has also been relocated ceutical companies have abandoned entrepreneurs to the Campus. many of these fields because they Another reason for this focus and companies see them as too risky. Our collabora- is that the Campus can unite two tion between different disciplines can approaches to treating neurological tackle them.’ conditions: biotech developments of In addition to neuroscience, the pharmaceuticals; and medtech devices Campus has a second focus on digi- such as the brain implants that now tal medicine. Masses of health data treat Parkinson’s disease. ‘We think is generated daily through mobile that the next generation of treatments applications, wearable technologies, computerised records and analytical disciplines such as genomics. Gath- ering and processing this data using digital forms of R&D such as model- ling, simulation and visualisation should provide information that can make treatments smarter. Opened in May 2015, Campus Biotech already has a workforce of 600, which is expected to climb to more than a thousand. The aim is to foster platforms that are open to anyone to work in – researchers, digital experts, engineers, entrepreneurs and compa- nies. ‘Use labs’ are available for non-employees where they can collab- orate on specific projects and return to their normal places of work when they are completed. Dr Dubuis is well-placed to work on such convergence issues. A chemical engineer by training, his doctorate was in biotechnology. He was Dean of the School of Life Sciences at EPFL and has worked with companies such as Ciba- Geigy and Lonza. He also co-founded Eclosion, the first Swiss Life Sciences seed-fund and incubator which helps researchers transform their laboratory findings into commercial products. In addition, he is President of BioAlps, a non-profit association that promotes the life sciences clus- ter of
Recommended publications
  • Medtech: the New Eldorado of Cyberhealth
    Campus Biotech Big data boosts Prostheses, a path the Russian doll bioinformatics to personalised of innovation P9 companies P21 medicine P22 ITZERLAND ITZERLAND 654 684321365 W 0122 20334895 6873543333 TERN S 0122 20334895 S 012220334895 74635135464 TER OF WE S MEDTECH: THE 654 CIENCE CLU NEW684321365 ELDORADO S OF CYBERHEALTH BASED ON ITS STRENGTH IN MEDICAL TECHNOLOGIES THE HEALTH VALLEY OF WESTERN SWITZERLAND , THE LIFE HAS CREATED AN IDEAL ECOSYSTEM FOR E-HEALTH S LP A 012220334895 UE ON BIO SS BioAlps 4 to 6: company profiles and business guide P36 SPECIAL I CONTENT FEATURES 14 Cyberhealth, a new El Dorado for Western Switzerland After biotechnology and the neurosciences, health is becoming an area of expertise in which universities and schools of higher education are positioning themselves, creating an ecosystem which is favourable for spawning start-ups. BY PASCAL VERMOT PHOTO LARGE VIEW NEW & VIEWS FEATURES BIOALPS 4TO6 BUSINESS GUIDE 9 Campus Biotech: 19 “Big Data” boosts 36 AC Immune 50 Bioalps The Russian bioinformatics Business Guide doll of Innovation 37 Productec 20 Enabling stem 11 ObsEva targets cell therapies 38 PhytoArk preterm birth 39 Cremo prevention 23 Medtech for small investors 40 CSL Behring 11 SAV-IOL’s life CONTENT without glasses 24 Prostheses, 41 FRM the avatars 12 Endosense taken of personalised 42 FKG Dentaire 4 From the editor over by St. Jude medicine 5 From the President 43 regenHu of BioAlps 12 3 questions to 26 Adolphe Merkle 44 Ceramaret 6 Techno-image: Jacques Essinger Institute’s Bionic hand. (Symetis)
    [Show full text]
  • A Hub for Personalized Health
    KEY FIGURES SWITZERLAND – A HUB FOR PERSONALIZED HEALTH 2 AT A GLANCE Swiss companies Thanks to its traditional strength in the life sciences sector and international ICT hotspots, in the Top 5 of the global pharmaceutical industry Switzerland offers the ideal environment for innovative companies that want to quick- (Roche + Novartis) ly and easily bring new innovations in personalized health to market. In Switzlerland, science and industry have a uniquely close relationship that guarantees fast technology transfer in a versatile and compact ecosystem. Cutting-edge research is carried out by Swiss pharmaceutical companies such as Roche and Novartis, at world-class universities 184 and government institutes; SMEs and startups provide important impetus for this. Switzer- CHF million nationwide investments in land is investing massively in harmonized data infrastructures, while at the same time personalized health placing great importance on data protection. 2017-2020 A selection of companies active in Switzerland 1 1st Personalized Health, by category Place – Best healthcare systems worldwide (EHCI) Data Analytics Disease + Health Healthcare Process Precision Medicine + Biognosyys Managment Solutions Optimization Diagnostics Sources: Euro Health Consumer Index Clinerion Advancience HCSG Abionic 2018; Start-up.ch; EY; BAG, 2019 Genedata Ava Komed Health Artidis Google AI MindMaze Medgate Bühlmann Laboratories IBM Research MiSanto MiSanto Limula biotech Novartis Lunaphore RetinAl ProteoMediX Sonogen Roche Sophia Genetics Tecan 4Quant Sources: BaselArea.swiss; Swiss Digital Health Map, 2019 OFFICIAL PROGRAM RESEARCH AND DEVELOPMENT (R&D) • In October 2019, Basel-based Novartis and Microsoft estab- • The closeness of the relationship between science and industry lished the AI Innovation Lab for developing intelligent and per- in Switzerland is unique.
    [Show full text]
  • Innovation in Life Sciences for Start-Ups and Companies
    Why Geneva is your best choice in Europe Innovation in life sciences for start-ups and companies www.whygeneva.ch Geneva-based life sciences companies explain what makes this ecosystem special Alcon Covance Eli Lilly Genomic Health Incyte Laboratoires Bailleul Linkage Biosciences Menicon Otsuka Santen Tasly Vifor Contents Commitment to innovation Geneva supports life science companies Strong to stronger: how a life sciences ecosystem grows 2 When a vaccine is found for Ebola, the “most Geneva’s commitment to life sciences companies 3 severe acute public health emergency seen in modern times”*, it will be in part thanks to the Campus Biotech: Geneva University Hospitals (HUG) where Innovation, collaboration, translation 4 clinical trials of the current best vaccine candi- Covance: Focusing on innovation 6 date are now underway. That this important work is happening in Geneva underlines two things Eli Lilly’s philosophy of exchange 8 special about our canton: the region’s expertise in life sciences and Geneva’s place at the center Alcon at the “center of healthcare innovation” 10 of international governance. For, if the HUG is here with all its scientific rigour and expertise, Vifor: Finding everything it needs 12 so is the World Health Organization, the Specialized service companies help International Red Cross, Doctors without Laboratoires Bailleul grow 13 Borders, the Global Fund, DNDi, FIND, MMV and the many other international organizations The world center of private / public cooperaton in health 14 and NGOs committed to public health
    [Show full text]
  • BIOMEDICAL CLUSTERS WORLDWIDE: SUCCESS FACTORS International Medical Cluster Foundation and BEST PRACTICES
    BIOMEDICAL CLUSTERS WORLDWIDE: SUCCESS FACTORS International Medical Cluster Foundation AND BEST PRACTICES Address: 5 Nikitskiy Pereulok, 6 bld., Moscow, 125009, Russia Phone: +7 (495) 139-24-44 https://mimc.global/ E-mail: [email protected] BIOMEDICAL CLUSTERS WORLDWIDE: SUCCESS FACTORS AND BEST PRACTICES BIOMEDICAL SUCCESS FACTORS CLUSTERS WORLDWIDE: Institute for Statistical Studies and Economics of Knowledge, National Research University Higher School of Economics Address: 20 Myasnitskaya Ulitsa, Moscow, 101000, Russia Phone: +7 (495) 621-28-73 https://issek.hse.ru/en/ E-mail: [email protected] HSE ISSEK Russian Cluster Observatory http://cluster.hse.ru E-mail: [email protected] BIOMEDICAL CLUSTERS WORLDWIDE: SUCCESS FACTORS AND BEST PRACTICES Mosсow 2019 Medical_Clusters_english_version.indd 1 20.03.2019 19:00:32 УДК [60:61]:332.12 ББК 65.495 B60 Editorial Board: Leonid Gokhberg, Mikhail Yugay Authors: Ekaterina Islankina, Evgeniy Kutsenko, Faina Filina, Victoria Pankevich, Elena Popova, and Valeriia Moiseieva Biomedical Clusters Worldwide: Success Factors and Best Practices / E. Islankina, E. Kutsenko, F. Filina, В60 V. Pankevich et al.; International Medical Cluster Foundation; National Research University Higher School of Economics. – Moscow: HSE, 2019. – 156 p. – 100 copies. – ISBN 978-5-7598-1958-5 (pbk). The report presents the results of a global study of biomedical clusters. Its goal is to identify and ana- lyse the most successful international practices of promoting biomedical clusters, in which the coope- ration of universities, firms and clinics, combined with a developed infrastructure and public support mea- sures led to a significant improvement in the quality of healthcare. The edition summarises the positive effects of biomedical clusters, describes their global landscape and reveals the key success factors, which are then compared with the features of the Moscow International Medical Cluster activities.
    [Show full text]
  • International Monitor | Country Factsheets Foreword
    International monitor Country factsheets 1 International monitor | Country factsheets Foreword Dear Reader, A sector-wide internationalisation policy requires priorities. Which countries should the Top Sector Life Sciences & Health (Health~Holland) focus on? On the basis of which criteria does a country or region receive a higher priority? Which efforts need to be made in which countries? The Health~Holland International Monitor is introduced within the context of the Health~Holland International Strategy so that these questions can be answered systematically. This International Monitor is a system for collecting and disclosing information about potential partner countries. For each country, the information available is brought together in country factsheets. Furthermore, the information is classified into categories to make it clear which efforts are desirable for which category of countries. Len de Jong Chair International Workgroup Top Sector Life Sciences & Health (Health~Holland) 2 International monitor | Country factsheets Contents Contents ...................................................................................................................................................... 3 Introduction ............................................................................................................................................... 4 ASEAN 5 ....................................................................................................................................................... 7 Belgium ....................................................................................................................................................
    [Show full text]
  • SWITZERLAND JUNE 2017 Acknowledgements
    TICINO: MILAN’S SWISS SPOTLIGHT ON GENEVA’S FUNDING BIOTECH ‘INDUSTRY 4.0’ - SUBURB? HEALTH VALLEY PAGE 38 SPOTLIGHT ON PROCESS PAGE 49 PAGE 12 AUTOMATION PAGE 14 A KALEIDOSCOPE OF EXCELLENCE page 21 SWITZERLAND JUNE 2017 Acknowledgements Pharmaboardroom would like to thank: Raymond Cron, CEO, Switzerland Innovation Nic Alexakis, CEO, Swiss Biotech Association Urs Gasche, president, FASMED Gilles Pluntz, chairman of Group Operating Committee & SVP Europe- Canada, Ferring Giorgio Calderari, chairman, Farma Industria Ticino (FIT) Riccardo Braglia, group vice chairman & CEO, Helsinn As well as all of the companies we have met for their support, assistance and enthusiasm. 2 Healthcare & Life Sciences Review: Switzerland www.pharmaboardroom.com HEALTHCARE & LIFE SCIENCES REVIEW SWITZERLAND Geneva: Switzerland’s Budding Health Valley Article 12 CONTENTS — June 2017 2 ACKNOWLEDGEMENTS 5 PREFACE 6 SNAPSHOT IN FIGURES A Kaleoidoscope 10 INVESTING IN WESTERN SWITZERLAND of Excellence INTERVIEW Thomas Bohn, Greater Geneva Bern area (GGBa) Cover story 21 12 GEO-SPACIAL FOCUS FEATURE West Switzertland 14 PROCESS AUTOMATION FEATURE Next-Gen Pharma Processes 16 HEALTH INSURANCE INTERVIEW Daniel Schmutz, Helsana 19 REGIONAL HEADQUARTERS INTERVIEW Shigeo Taniuchi, Santen 21 A KALEIDOSCOPE OF EXCELLENCE COVER STORY 22 World-Class Service Providers 26 The Essence of Swissness 31 Market Quirkness 34 Digital Prowess 38 Swiss Biotech’s Funding Quandary 41 Mid-Caps and Minnows: at the Vanguard of Creativity Interview with Gilles Pluntz, SVP Europe- 46 Cluster of Clusters Canada at Ferring 47 Decision Points Interview 61 49 Ticino: Milan’s Swiss Suburb? 52 Ticino: Bastion of Pharma Services The Healhcare & Life Sciences Review was produced 55 ‘Sonderfall Schweiz’ by PharmaBoardroom.
    [Show full text]
  • See the Publication
    THE WORLD’S BEST HOSPITALS 2021 This year’s ranking of the premier destinations for acute medical care around the globe and in the U.S., including the best American hospitals for infection prevention. GETTY CREDIT CREDIT 34 NEWSWEEK.COM MARCh 12, 2021 Illustrations by OKSANA GRIVINA NEWSWEEK.COM 35 WORLD’S BEST HOSPITALS 2021 METHODOLOGY THE EXPERTS Provided guidance and methodological input for the rankings THE ‌‌WORLD’S BEST HOSPITALS same country, because dif- DAVID W. BATES, M.D. GREGORY KATZ ranking lists the best ferent sources for patient Brigham and Women’s University of Paris School hospitals in 25 countries: experience and medical Hospital, Boston of Medicine, Paris USA, Germany, Japan, South KPIs were examined in Korea, France, Italy, United each country. Since it was Chief of the division of general internal A professor at the University of Paris medicine and primary care at Brigham School of Medicine, Gregory Katz holds Kingdom, Spain, Brazil, Can- not possible to harmonize and Women’s Hospital, Bates is also a the Chair of Innovation & Value in Health. ada, India, Australia, Mexico, this data, cross-country professor at Harvard Medical School He is also president of PromTime, The Netherlands, Poland, comparisons of the scores and the Harvard School of Public Health a health data science company spe- Austria, Thailand, Swit- are not possible (example: and serves as medical director of clinical cialized in Value-Based Health Care, zerland, Sweden, Belgium, A score of 90 in country A and quality analysis for Partners Health- commissioned by the French Ministry Care in Boston. Internationally recog- of Health to incentivize practitioners on Finland, Norway, Denmark, doesn’t necessarily mean nized for his research on using medical high-value care.
    [Show full text]
  • Highlights 2017
    Highlights 2017 1 2017 in brief A very positive result In an uncertain economic and political environment, marked by the shock of Brexit, the unpredictability of Trump’s presidency and the rejection of the Corporate Tax Reform III, the results of our business development activities were very good in 2017. Western Switzerland achieved its best year on the American and Chinese markets, despite an increased international competition for the establishment of companies. 2 Quality above quantity The strategy adopted by the GGBa over the past few years, Outlook for 2018 which consists in prioritizing the quality rather than the quantity of the investment projects, keeps bearing fruit. Working in an unstable and extremely competitive Most of the companies established in Western Switzerland Brexit : a targeted approach environment, the GGBa remains nimble and continues to in 2017 are active in the very high-tech sectors of life focus on high value-added projects. With a professional sciences, information and communication technology The United Kingdom is traditionally one of Switzerland’s and motivated team, a clear strategy and adapted tools, and precision engineering. The GGBa contributes to main competitors in the field of foreign direct investments. and thanks to the excellent collaboration between all the the present and future prosperity of the region. London, in particular, hosts 40% of the European players of the investment promotion network, the GGBa headquarters of the Top 250 international groups. is confident and optimistic for the future. Following the referendum of June 2016, the GGBa reacted quickly in order to evaluate the opportunities linked to Strengthening the positioning the Brexit, before undertaking targeted prospecting of Western Switzerland activities in the sectors of IT, fintech and life sciences.
    [Show full text]
  • Technology by Bilan 2016
    SPECIAL ISSUE ON BIOALPS, THE LIFE SCIENCE CLUSTER OF WESTERN SWITZERLAND technologyBY BioAlps 4 à 6: compagny profiles and business guide P38 INSIDE THE SECRETS OF THE BRAIN WESTERN SWITZERLAND’S BUOYANT NEUROSCIENCES CLUSTER TRANSLATES RESEARCH INTO INNOVATIONS 2 CONTENTS EDITORIAL 3 The brains who uncover the secrets of the brain How to explain a biological one of the most noble missions science can pursue, be- machine that contains 100 billion neurons each inter- cause taxpayers who support universities also happen connected by an average of between 1,000 and 10,000 to be patients. Neuropathologies account for a third of synapses to allow information to circulate at speeds of health-related costs in Europe. With ageing, the number up to 120 metres a second? How to explain emotions, of people aff ected by Alzheimers and Parkinsons is due consciences, dreams or love? And beyond that, how to explode in the coming years, threatening the econo- can you diagnose and cure the vast range of nervous mic viability of health systems as underlined by neuro system-related diseases that aff ect no fewer than one startup business angel Martin Velasco (see page 23). in three people worldwide? Strokes are the leading cause of handicap. Multiple scle- Explaining the brain, one of the last great frontiers of rosis aff ects 3 million people, placing an unbearable toll 14 science, is the fi rst critical mission of Campus Biotech on families, friends and social (see page 14) a futuristic facility in the heart of Geneva workers. And the list goes on. supporting 750 neuroscientists, engineers, psychiatrists, Because there are few if any Campus Biotech: Brains inside technologists, medical doctors..
    [Show full text]